EUVIMEDEUVIMED entdecken
Crossref

Selenium nanoparticles and paclitaxel co-delivery by a PCL based nanofibrous scaffold to enhance melanoma therapy

Maryam Doostan, Ata'ollah Rahmani Azar, Hassan Maleki iD

Journal of Biomaterials Applications · 2025

DOI: 10.1177/08853282251330724 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomaterials Applications, 2025. Verfasst von Maryam Doostan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Kermanshah University of Medical Sciences, Kermanshah, Iran. Hauptthemen laut MEDLINE: Polyesters, Selenium, Paclitaxel, Nanofibers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Deputy for Research and Technology, Kermanshah University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The incidence of skin cancer has increased significantly in recent decades, highlighting the need for more effective treatments due to the limitations of traditional approaches. This study focused on creating a poly (ε-caprolactone) and chitosan (PCL/CS) nanofibrous scaffold loaded with selenium nanoparticles (Se NPs) and paclitaxel (PTX) to inhibit melanoma cell growth. The synthesized Se NPs, characterized by their uniform spherical shape and nano-scale size (∼120 nm), were incorporated into the scaffold. Then, the Se NPs and PTX were concurrently loaded into PCL/CS nanofibers at 5 wt%, which resulted in fibers with an average diameter of 253 ± 35 nm, presenting a ribbon-like morphology and absence of droplets/beads. The results indicated a high fluid absorption capacity, a wettability and high tensile strength of the produced scaffold. Moreover, the controlled release of the loaded compounds was provided over several days. Remarkably, high toxicity (>90%) and higher levels of apoptosis (>85%) were observed in A375 melanoma cells treated with the PTX-Se NPs PCL/CS scaffold. Moreover, the assessment of fibroblast growth and hemolysis confirmed the scaffold’s high level of biocompatibility. The PTX-Se NPs PCL/CS nanofibers exhibit favorable properties and strong anti-tumor efficacy, making them a promising scaffold for localized and selective chemotherapy in anti-melanoma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PolyestersSeleniumPaclitaxelNanofibersMelanomaNanoparticlesAntineoplastic Agents, PhytogenicHumansCell Line, TumorChitosanTissue ScaffoldsApoptosisDrug LiberationDelayed-Action PreparationsCell SurvivalDrug Carriers

Stichwörter der Autor:innen

Se nanoparticleapoptosiscytotoxicityelectrospinningmelanomananofiber

Substanzen

PolyestersSeleniumpolycaprolactonePaclitaxelChitosanAntineoplastic Agents, PhytogenicDelayed-Action PreparationsDrug Carriers

Autor:innen und Institutionen

  • Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

ORCID-Profile: Hassan Maleki

Förderung

  • Deputy for Research and Technology, Kermanshah University of Medical Sciences

Zitieren

APA

Doostan, M., Rahmani Azar, A., & Maleki, H. (2025). Selenium nanoparticles and paclitaxel co-delivery by a PCL based nanofibrous scaffold to enhance melanoma therapy. Journal of Biomaterials Applications. https://doi.org/10.1177/08853282251330724

Vancouver

Doostan M, Rahmani Azar A, Maleki H. Selenium nanoparticles and paclitaxel co-delivery by a PCL based nanofibrous scaffold to enhance melanoma therapy. Journal of Biomaterials Applications. 2025. doi:10.1177/08853282251330724

BibTeX
@article{Doostan2025,
  author = {Doostan, Maryam and Rahmani Azar, Ata'ollah and Maleki, Hassan},
  title = {Selenium nanoparticles and paclitaxel co-delivery by a PCL based nanofibrous scaffold to enhance melanoma therapy},
  journal = {Journal of Biomaterials Applications},
  year = {2025},
  doi = {10.1177/08853282251330724}
}
Kostenlos starten →